Gardner, Thomas J.
Lee, J. Peter http://orcid.org/0000-0003-4507-046X
Bourne, Christopher M. http://orcid.org/0000-0001-9290-4223
Wijewarnasuriya, Dinali
Kinarivala, Nihar http://orcid.org/0000-0002-0320-7600
Kurtz, Keifer G.
Corless, Broderick C.
Dacek, Megan M. http://orcid.org/0000-0003-1731-1502
Chang, Aaron Y. http://orcid.org/0000-0002-7770-7405
Mo, George
Nguyen, Kha M. http://orcid.org/0000-0002-8621-8603
Brentjens, Renier J. http://orcid.org/0000-0002-3364-5388
Tan, Derek S. http://orcid.org/0000-0002-7956-9659
Scheinberg, David A. http://orcid.org/0000-0002-4160-923X
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P01 CA023766, R01 CA55349, R35 CA241894, R01 AI118224, P30 CA008748)
Tudor Fund (DAS), Lymphoma Fund (DAS), Commonwealth Foundation and MSK Center for Experimental Therapeutics
See TAN entry
Article History
Received: 23 December 2020
Accepted: 21 October 2021
First Online: 30 December 2021
Competing interests
: D.A.S., D.S.T. and R.J.B. are consultants for, have equity in and have sponsored research agreements with CoImmune, which has licensed technology described in this paper from MSK. D.A.S. has equity in or is a consultant for: Actinium Pharmaceuticals, Arvinas, Eureka Therapeutics, Iovance Biotherapeutics, OncoPep, Pfizer, Repretoire and Sellas. D.S.T. has been a consultant and/or paid speaker for Eli Lilly, Elsevier, Emerson Collective, Merck, National Institutes of Health, Venenum Biodesign, the Research Center for Molecular Medicine of the Austrian Academy of Sciences and the Institute for Research in Biomedicine, Barcelona. R.J.B. is a cofounder and receives royalties from Juno Therapeutics/Celgene. MSK has filed for patent protection behalf of T.J.G., J.P.L., D.S.T. and D.A.S. for inventions described in this paper. The remaining authors declare no competing interests.